Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 9717530, 15 pages
http://dx.doi.org/10.1155/2016/9717530
Review Article

Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets

1Department of Dermatology, University Hospital of Zurich, University of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
2Department of Infectology and Dermatology, Riga Stradins University, Riga, Latvia
3Department of Dermatology, Christian-Albrechts-University Kiel, Kiel, Germany

Received 4 December 2015; Accepted 30 March 2016

Academic Editor: Arjen F. Nikkels

Copyright © 2016 Ieva Saulite et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. Campbell, R. A. Clark, R. Watanabe, and T. S. Kupper, “Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors,” Blood, vol. 116, no. 5, pp. 767–771, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Clark, J. B. Shackelton, R. Watanabe et al., “High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma,” Blood, vol. 117, no. 6, pp. 1966–1976, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Willemze, E. S. Jaffe, G. Burg et al., “WHO-EORTC classification for cutaneous lymphomas,” Blood, vol. 105, no. 10, pp. 3768–3785, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. M. H. Imam, P. J. Shenoy, C. R. Flowers, A. Phillips, and M. J. Lechowicz, “Incidence and survival patterns of cutaneous T-cell lymphomas in the United States,” Leukemia and Lymphoma, vol. 54, no. 4, pp. 752–759, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. P. T. Bradford, S. S. Devesa, W. F. Anderson, and J. R. Toro, “Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases,” Blood, vol. 113, no. 21, pp. 5064–5073, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. J. Scarisbrick, H. M. Prince, M. H. Vermeer et al., “Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model,” Journal of Clinical Oncology, vol. 33, no. 32, pp. 3766–3773, 2015. View at Publisher · View at Google Scholar
  7. E. Olsen, E. Vonderheid, N. Pimpinelli et al., “Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC),” Blood, vol. 110, no. 6, pp. 1713–1722, 2007. View at Google Scholar
  8. E. C. Vonderheid, M. G. Bernengo, G. Burg et al., “Update on erythrodermic cutaneous T-cell lymphoma: report of the international society for cutaneous lymphomas,” Journal of the American Academy of Dermatology, vol. 46, no. 1, pp. 95–106, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. C. D. Klemke, N. Booken, C. Weiss et al., “Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases,” British Journal of Dermatology, vol. 173, no. 1, pp. 93–105, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Weidinger and N. Novak, “Atopic dermatitis,” The Lancet, vol. 387, no. 10023, pp. 1109–1122, 2016. View at Publisher · View at Google Scholar
  11. J. S. Margolis, K. Abuabara, W. Bilker, O. Hoffstad, and D. J. Margolis, “Persistence of mild to moderate atopic dermatitis,” JAMA Dermatology, vol. 150, no. 6, pp. 593–600, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. I. Silverberg and J. M. Hanifin, “Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study,” Journal of Allergy and Clinical Immunology, vol. 132, no. 5, pp. 1132–1138, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Biedermann, Y. Skabytska, S. Kaesler, and T. Volz, “Regulation of T cell immunity in atopic dermatitis by microbes: the Yin and Yang of cutaneous inflammation,” Frontiers in Immunology, vol. 6, article 353, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Suga, M. Sugaya, T. Miyagaki et al., “Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous t-cell lymphoma,” Clinical Cancer Research, vol. 20, no. 16, pp. 4339–4348, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Kezic, N. Novak, I. Jakasa et al., “Skin barrier in atopic dermatitis,” Frontiers in Bioscience, vol. 19, no. 3, pp. 542–556, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Talpur, R. Bassett, and M. Duvic, “Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome,” British Journal of Dermatology, vol. 159, no. 1, pp. 105–112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Guenova, W. Hoetzenecker, S. Rozati, M. P. Levesque, R. Dummer, and A. Cozzio, “Novel therapies for cutaneous T-cell lymphoma: what does the future hold?” Expert Opinion on Investigational Drugs, vol. 23, no. 4, pp. 457–467, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Miyagaki and M. Sugaya, “Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis,” Journal of Dermatological Science, vol. 64, no. 1, pp. 1–6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. C. Cather, E. A. Vance, and M. A. Menter, “Diverse cutaneous manifestations associated with a single disease,” Proceedings (Baylor University. Medical Center), vol. 15, no. 4, pp. 433–436, 2002. View at Google Scholar
  20. L. Parmentier, C. Dürr, E. Vassella, H. Beltraminelli, L. Borradori, and E. Haneke, “Specific nail alterations in cutaneous T-cell lymphoma: successful treatment with topical mechlorethamine,” Archives of Dermatology, vol. 146, no. 11, pp. 1287–1291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Y. Bi, J. L. Curry, A. M. Christiano et al., “The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome,” Journal of the American Academy of Dermatology, vol. 64, no. 1, pp. 53–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. B. E. Jr. Cook, G. B. Bartley, M. R. Pittelkow, and R. H. Kennedy, “Ophthalmic abnormalities in patients with cutaneous T-cell lymphoma,” Transactions of the American Ophthalmological Society, vol. 96, pp. 309–327, 1998. View at Google Scholar · View at Scopus
  23. K. Mehrany, R. A. El-Azhary, S. A. Bouwhuis, and M. R. Pittelkow, “Cutaneous T-cell lymphoma and atopy: is there an association?” British Journal of Dermatology, vol. 149, no. 5, pp. 1013–1017, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Rajka and R. K. Winkelmann, “Atopic dermatitis and Sezary syndrome,” Archives of Dermatology, vol. 120, no. 1, pp. 83–84, 1984. View at Publisher · View at Google Scholar · View at Scopus
  25. C. W. Van Haselen, J. Toonstra, A. H. Preesman, S. C. J. Van Der Putte, C. A. F. M. Bruijnzeel-Koomen, and W. A. Van Vloten, “Sezary syndrome in a young man with severe atopic dermatitis,” British Journal of Dermatology, vol. 140, no. 4, pp. 704–707, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. E. A. Abel, B. J. Nickoloff, D. M. Shelby, W. Watson, and G. S. Wood, “Tumor stage mycosis fungoides in a patient treated with long-term corticosteroids for asthma and atopic-like dermatitis,” Journal of Dermatologic Surgery and Oncology, vol. 12, no. 10, pp. 1089–1093, 1986. View at Publisher · View at Google Scholar · View at Scopus
  27. E. C. Vonderheid, “On the diagnosis of erythrodermic cutaneous T-cell lymphoma,” Journal of Cutaneous Pathology, vol. 33, supplement 1, pp. 27–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Russell-Jones, “Diagnosing erythrodermic cutaneous T-cell lymphoma,” British Journal of Dermatology, vol. 153, no. 1, pp. 1–5, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. P. E. LeBoit, “Simulators of cutaneous lymphoma where should our efforts go?” American Journal of Clinical Pathology, vol. 139, no. 4, pp. 414–417, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Bieber, “Atopic dermatitis,” New England Journal of Medicine, vol. 358, no. 14, pp. 1430–1494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Katsarou and M. C. Armenaka, “Atopic dermatitis in older patients: particular points,” Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 1, pp. 12–18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Ozkaya, “Adult-onset atopic dermatitis,” Journal of the American Academy of Dermatology, vol. 52, no. 4, pp. 579–582, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Guenova, R. Watanabe, J. E. Teague et al., “TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma,” Clinical Cancer Research, vol. 19, no. 14, pp. 3755–3763, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Guenova, T. Volz, K. Sauer et al., “IL-4-mediated fine tuning of IL-12p70 production by human DC,” European Journal of Immunology, vol. 38, no. 11, pp. 3138–3149, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. H. Vermeer, R. van Doorn, D. Dukers, M. W. Bekkenk, C. J. L. M. Meijer, and R. Willemze, “CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior,” Journal of Clinical Oncology, vol. 19, no. 23, pp. 4322–4329, 2001. View at Google Scholar · View at Scopus
  36. G. Goteri, A. Filosa, B. Mannello et al., “Density of neoplastic lymphoid infiltrate, CD8+ T cells, and CD1a+ dendritic cells in mycosis fungoides,” Journal of Clinical Pathology, vol. 56, no. 6, pp. 453–458, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. S. I. Jawed, P. L. Myskowski, S. Horwitz, A. Moskowitz, and C. Querfeld, “Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers,” Journal of the American Academy of Dermatology, vol. 70, no. 2, pp. 205.e1–205.e16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. L. M. Gjerdrum, A. Woetmann, N. Odum et al., “FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival,” Leukemia, vol. 21, no. 12, pp. 2512–2518, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Krejsgaard, N. Odum, C. Geisler, M. A. Wasik, and A. Woetmann, “Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome,” Leukemia, vol. 26, no. 3, pp. 424–432, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Ni, P. Hazarika, C. Zhang, R. Talpur, and M. Duvic, “Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?” Clinical Cancer Research, vol. 7, no. 9, pp. 2682–2692, 2001. View at Google Scholar · View at Scopus
  41. C. L. Berger, R. Tigelaar, J. Cohen et al., “Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells,” Blood, vol. 105, no. 4, pp. 1640–1647, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Dummer, P. W. Heald, F. O. Nestle et al., “Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain),” Blood, vol. 88, no. 4, pp. 1383–1389, 1996. View at Google Scholar
  43. T. Krejsgaard, U. Ralfkiaer, E. Clasen-Linde et al., “Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/stat3 signaling pathway,” Journal of Investigative Dermatology, vol. 131, no. 6, pp. 1331–1338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Papadavid, J. Economidou, A. Psarra et al., “The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome,” British Journal of Dermatology, vol. 148, no. 4, pp. 709–718, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. B. R. Vowels, M. Cassin, E. C. Vonderheid, and A. H. Rook, “Aberrant cytokine production by sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells,” Journal of Investigative Dermatology, vol. 99, no. 1, pp. 90–94, 1992. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Kari, A. Loboda, M. Nebozhyn et al., “Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma,” Journal of Experimental Medicine, vol. 197, no. 11, pp. 1477–1488, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. B. R. Vowels, S. R. Lessin, M. Cassin et al., “Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma,” Journal of Investigative Dermatology, vol. 103, no. 5, pp. 669–673, 1994. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Rübben, W. Kempf, M. E. Kadin, D. R. Zimmermann, and G. Burg, “Multilineage progression of genetically unstable tumor subclones in cutaneous T-cell lymphoma,” Experimental Dermatology, vol. 13, no. 8, pp. 472–483, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Yawalkar, K. Ferenczi, D. A. Jones et al., “Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma,” Blood, vol. 102, no. 12, pp. 4059–4066, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Y. Leung and T. Bieber, “Atopic dermatitis,” The Lancet, vol. 361, no. 9352, pp. 151–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. J. K. Gittler, A. Shemer, M. Suarez-Farinas et al., “Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 130, no. 6, pp. 1344–1354, 2012. View at Google Scholar
  52. T. Biedermann, M. Röcken, and J. M. Carballido, “TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin,” Journal of Investigative Dermatology Symposium Proceedings, vol. 9, no. 1, pp. 5–14, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Volz, Y. Skabytska, E. Guenova et al., “Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells,” Journal of Investigative Dermatology, vol. 134, no. 1, pp. 96–104, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Skabytska, F. Wölbing, C. Günther et al., “Cutaneous innate immune sensing of toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells,” Immunity, vol. 41, no. 5, pp. 762–775, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. V. Soumelis, P. A. Reche, H. Kanzler et al., “Human epithelial cells trigger dendritic cell−mediated allergic inflammation by producing TSLP,” Nature Immunology, vol. 3, no. 7, pp. 673–680, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Matsumoto, C. Ra, K. Kawamoto et al., “IgE hyperproduction through enhanced tyrosine phosphorylation of janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis,” Journal of Immunology, vol. 162, no. 2, pp. 1056–1063, 1999. View at Google Scholar · View at Scopus
  57. Y. Kataoka, “Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis,” Journal of Dermatology, vol. 41, no. 3, pp. 221–229, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Thijs, T. Krastev, S. Weidinger et al., “Biomarkers for atopic dermatitis: a systematic review and meta-analysis,” Current Opinion in Allergy and Clinical Immunology, vol. 15, no. 5, pp. 453–460, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. E. J. Kim, S. Hess, S. K. Richardson et al., “Immunopathogenesis and therapy of cutaneous T cell lymphoma,” The Journal of Clinical Investigation, vol. 115, no. 4, pp. 798–812, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Lu, M. Duvic, L. J. Medeiros, R. Luthra, D. M. Dorfman, and D. Jones, “The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides,” American Journal of Clinical Pathology, vol. 115, no. 3, pp. 413–421, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Grewe, S. Walther, K. Gyufko, W. Czech, E. Schopf, and J. Krutmann, “Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients,” Journal of Investigative Dermatology, vol. 105, no. 3, pp. 407–410, 1995. View at Publisher · View at Google Scholar · View at Scopus
  62. R. A. Taha, D. Y. M. Leung, O. Ghaffar, M. Boguniewicz, and Q. Hamid, “In vivo expression of cytokine receptor mRNA in atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 102, no. 2, pp. 245–250, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Kaesler, T. Volz, Y. Skabytska et al., “Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10,” Journal of Allergy and Clinical Immunology, vol. 134, no. 1, pp. 92.e6–99.e6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Kasprzycka, Q. Zhang, A. Witkiewicz et al., “γc-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes,” Journal of Immunology, vol. 181, no. 4, pp. 2506–2512, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Krejsgaard, L. M. Gjerdrum, E. Ralfkiaer et al., “Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome,” Leukemia, vol. 22, no. 12, pp. 2230–2239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Bagot, M. Nikolova, F. Schirm-Chabanette, J. Wechsler, L. Boumsell, and A. Bensussan, “Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas,” Annals of the New York Academy of Sciences, vol. 941, pp. 31–38, 2001. View at Google Scholar · View at Scopus
  67. H. T. Jin, R. Ahmed, and T. Okazaki, “Role of PD-1 in regulating T-cell immunity,” in Negative Co-Receptors and Ligands, vol. 350 of Current Topics in Microbiology and Immunology, pp. 17–37, Springer, Berlin, Germany, 2011. View at Publisher · View at Google Scholar
  68. F. Çetinözman, P. M. Jansen, M. H. Vermeer, and R. Willemze, “Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides,” Archives of Dermatology, vol. 148, no. 12, pp. 1379–1385, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Samimi, B. Benoit, K. Evans et al., “Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression,” Archives of Dermatology, vol. 146, no. 12, pp. 1382–1388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Contassot, K. Kerl, S. Roques et al., “Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sézary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression,” Blood, vol. 111, no. 9, pp. 4780–4787, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. O. Dereure, E. Levi, E. C. Vonderheid, and M. E. Kadin, “Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin,” Journal of Investigative Dermatology, vol. 118, no. 6, pp. 949–956, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. O. Dereure, P. Portales, J. Clot, and J.-J. Guilhou, “Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas,” British Journal of Dermatology, vol. 143, no. 6, pp. 1205–1210, 2000. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Wu, M. Nihal, J. Siddiqui, E. C. Vonderheid, and G. S. Wood, “Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation,” Journal of Investigative Dermatology, vol. 129, no. 5, pp. 1165–1173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. C. L. Jones, E. M. Wain, C.-C. Chu et al., “Downregulation of fas gene expression in sézary syndrome is associated with promoter hypermethylation,” Journal of Investigative Dermatology, vol. 130, no. 4, pp. 1116–1125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. R. van Doorn, R. Dijkman, M. H. Vermeer, T. M. Starink, R. Willemze, and C. P. Tensen, “A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma,” Cancer Research, vol. 62, no. 19, pp. 5389–5392, 2002. View at Google Scholar · View at Scopus
  76. Y. Reiss, A. E. Proudfoot, C. A. Power, J. J. Campbell, and E. C. Butcher, “CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin,” Journal of Experimental Medicine, vol. 194, no. 10, pp. 1541–1547, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Ferenczi, R. C. Fuhlbrigge, J. L. Pinkus, G. S. Pinkus, and T. S. Kupper, “Increased CCR4 expression in cutaneous T cell lymphoma,” Journal of Investigative Dermatology, vol. 119, no. 6, pp. 1405–1410, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. T. Kakinuma, M. Sugaya, K. Nakamura et al., “Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides,” Journal of the American Academy of Dermatology, vol. 48, no. 1, pp. 23–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Robert and T. S. Kupper, “Inflammatory skin diseases, T cells, and immune surveillance,” New England Journal of Medicine, vol. 341, no. 24, pp. 1817–1828, 1999. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Yagi, N. Seo, A. Ohshima et al., “Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: Immunohistochemical staining and in vitro chemotactic assay,” American Journal of Surgical Pathology, vol. 30, no. 9, pp. 1111–1119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Yamaguchi, K. Ohshima, T. Tsuchiya et al., “The comparison of expression of cutaneous lymphocyte-associated antigen (CLA), and Th1- and Th2-associated antigens in mycosis fungoides and cutaneous lesions of adult T-cell leukemia/lymphoma,” European Journal of Dermatology, vol. 13, no. 6, pp. 553–559, 2003. View at Google Scholar · View at Scopus
  82. M. Sokolowska-Wojdylo, J. Wenzel, E. Gaffal et al., “Circulating clonal CLA+ and CD4+ T cells in Sézary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7,” British Journal of Dermatology, vol. 152, no. 2, pp. 258–264, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Kallinich, J. M. Muche, S. Qin, W. Sterry, H. Audring, and R. A. Kroczek, “Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides,” Journal of Investigative Dermatology, vol. 121, no. 5, pp. 1045–1052, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. M. G. Narducci, E. Scala, A. Bresin et al., “Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV,” Blood, vol. 107, no. 3, pp. 1108–1115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Capriotti, E. C. Vonderheid, C. J. Thoburn, E. C. Bright, and A. D. Hess, “Chemokine receptor expression by leukemic T cells of cutaneous T-cell lymphoma: clinical and histopathological correlations,” Journal of Investigative Dermatology, vol. 127, no. 12, pp. 2882–2892, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. C. L. Tendler, J. D. Burton, J. Jaffe et al., “Abnormal cytokine expression in Sézary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies,” Cancer Research, vol. 54, no. 16, pp. 4430–4435, 1994. View at Google Scholar · View at Scopus
  87. M. Sugaya, “Chemokines and cutaneous lymphoma,” Journal of Dermatological Science, vol. 59, no. 2, pp. 81–85, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. U. Forssmann, M. Uguccioni, P. Loetscher et al., “Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes,” Journal of Experimental Medicine, vol. 185, no. 12, pp. 2171–2176, 1997. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Sallusto, C. R. Mackay, and A. Lanzavecchia, “Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells,” Science, vol. 277, no. 5334, pp. 2005–2007, 1997. View at Publisher · View at Google Scholar · View at Scopus
  90. T. Miyagaki, M. Sugaya, H. Fujita et al., “Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-Cell lymphoma,” Journal of Investigative Dermatology, vol. 130, no. 9, pp. 2304–2311, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. N. Berkman, S. Ohnona, F. K. Chung, and R. Breuer, “Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge,” American Journal of Respiratory Cell and Molecular Biology, vol. 24, no. 6, pp. 682–687, 2001. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Kagami, T. Kakinuma, H. Saeki et al., “Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis,” Clinical and Experimental Immunology, vol. 134, no. 2, pp. 309–313, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Ebner, V. A. Nguyen, M. Forstner et al., “Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells,” Journal of Allergy and Clinical Immunology, vol. 119, no. 4, pp. 982–990, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Yoo, M. Omori, D. Gyarmati et al., “Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin,” Journal of Experimental Medicine, vol. 202, no. 4, pp. 541–549, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Miyagaki and M. Sugaya, “Immunological milieu in mycosis fungoides and Sézary syndrome,” Journal of Dermatology, vol. 41, no. 1, pp. 11–18, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. N. K. Mollanazar, P. K. Smith, and G. Yosipovitch, “Mediators of chronic pruritus in atopic dermatitis: getting the itch out?” Clinical Reviews in Allergy and Immunology, 2015. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Sokołowska-Wojdyło, J. Gleń, M. Zabłotna et al., “Association of distinct IL-31 polymorphisms with pruritus and severity of atopic dermatitis,” Journal of the European Academy of Dermatology and Venereology, vol. 27, no. 5, pp. 662–664, 2013. View at Publisher · View at Google Scholar
  98. K. Hartmann, N. Wagner, A. Rabenhorst et al., “Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients,” Journal of Allergy and Clinical Immunology, vol. 132, no. 1, pp. 232–e4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Möbs, S. Gryzik, A. Haidar, D. Humme, M. Beyer, and S. Vandersee, “Analysis of the IL-31 pathway in mycosis fungoides and sézary syndrome,” Archives of Dermatological Research, vol. 307, no. 6, pp. 479–485, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. P. Y. Ong, T. Ohtake, C. Brandt et al., “Endogenous antimicrobial peptides and skin infections in atopic dermatitis,” The New England Journal of Medicine, vol. 347, no. 15, pp. 1151–1160, 2002. View at Publisher · View at Google Scholar · View at Scopus
  101. I. Nomura, E. Goleva, M. D. Howell et al., “Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes,” The Journal of Immunology, vol. 171, no. 6, pp. 3262–3269, 2003. View at Publisher · View at Google Scholar · View at Scopus
  102. M. D. Howell, A. Wollenberg, R. L. Gallo et al., “Cathelicidin deficiency predisposes to eczema herpeticum,” Journal of Allergy and Clinical Immunology, vol. 117, no. 4, pp. 836–841, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. P. I. Axelrod, B. Lorber, and E. C. Vonderheid, “Infections complicating mycosis fungoides and sézary syndrome,” The Journal of the American Medical Association, vol. 267, no. 10, pp. 1354–1358, 1992. View at Publisher · View at Google Scholar · View at Scopus
  104. C. M. Jackow, J. C. Cather, V. Hearne, A. T. Asano, J. M. Musser, and M. Duvic, “Association of erythrodermic cutaneous T-cell lymphoma, superantigen- positive Staphylococcus aureus, and oligoclonal T-cell receptor Vβ gene expansion,” Blood, vol. 89, no. 1, pp. 32–40, 1997. View at Google Scholar · View at Scopus
  105. V. Nguyen, R. H. Huggins, T. Lertsburapa et al., “Cutaneous T-cell lymphoma and Staphylococcus aureus colonization,” Journal of the American Academy of Dermatology, vol. 59, no. 6, pp. 949–952, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. S. J. K. Gilani, M. Gonzalez, I. Hussain, A. Y. Finlay, and G. K. Patel, “Staphylococcus aureus re-colonization in atopic dermatitis: beyond the skin,” Clinical and Experimental Dermatology, vol. 30, no. 1, pp. 10–13, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. A. Roll, A. Cozzio, B. Fischer, and P. Schmid-Grendelmeier, “Microbial colonization and atopic dermatitis,” Current Opinion in Allergy and Clinical Immunology, vol. 4, no. 5, pp. 373–378, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Nobbe, P. Dziunycz, B. Mühleisen et al., “IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis,” Acta Dermato-Venereologica, vol. 92, no. 1, pp. 24–28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. E. Sonkoly, A. Muller, A. I. Lauerma et al., “IL-31: a new link between T cells and pruritus in atopic skin inflammation,” Journal of Allergy and Clinical Immunology, vol. 117, no. 2, pp. 411–417, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. V. H. Sommer, O. J. Clemmensen, O. Nielsen et al., “In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3,” Leukemia, vol. 18, no. 7, pp. 1288–1295, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. K. Asadullah, W.-D. Döcke, A. Haeuler, W. Sterry, and H.-D. Volk, “Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA,” Journal of Investigative Dermatology, vol. 107, no. 6, pp. 833–837, 1996. View at Publisher · View at Google Scholar · View at Scopus
  112. T. Krejsgaard, A. Willerslev-Olsen, L. M. Lindahl et al., “Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation,” Blood, vol. 124, no. 5, pp. 761–770, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. Y. Tokura, H. Yagi, A. Ohshima et al., “Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: a potential role for bacterial superantigens,” British Journal of Dermatology, vol. 133, no. 1, pp. 6–12, 1995. View at Google Scholar · View at Scopus
  114. H. K. Wong, A. Mishra, T. Hake, and P. Porcu, “Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and sezary syndrome),” British Journal of Haematology, vol. 155, no. 2, pp. 150–166, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. E. Guenova, Y. Skabytska, W. Hoetzenecker et al., “IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 7, pp. 2163–2168, 2015. View at Publisher · View at Google Scholar · View at Scopus
  116. R. Dummer, S. Rozati, E. Guenova, and A. Cozzio, “Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas,” Future Oncology, vol. 9, no. 8, pp. 1061–1064, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. F. Trautinger, R. Knobler, R. Willemze et al., “EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome,” European Journal of Cancer, vol. 42, no. 8, pp. 1014–1030, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. R. Sidbury, D. M. Davis, D. E. Cohen et al., “Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents,” Journal of the American Academy of Dermatology, vol. 71, no. 2, pp. 327–349, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. E. A. Olsen, A. H. Rook, J. Zic et al., “Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC),” Journal of the American Academy of Dermatology, vol. 64, no. 2, pp. 352–404, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. J. Guitart, S. C. Wickless, Y. Oyama et al., “Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma,” Archives of Dermatology, vol. 138, no. 10, pp. 1359–1365, 2002. View at Google Scholar · View at Scopus
  121. C. Querfeld, S. T. Rosen, T. M. Kuzel et al., “Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy,” Archives of Dermatology, vol. 141, no. 3, pp. 305–311, 2005. View at Publisher · View at Google Scholar · View at Scopus
  122. Y. Mansouri and E. Guttman-Yassky, “Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics,” Journal of Clinical Medicine, vol. 4, no. 5, pp. 858–873, 2015. View at Publisher · View at Google Scholar
  123. J. Lundin, H. Hagberg, R. Repp et al., “Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome,” Blood, vol. 101, no. 11, pp. 4267–4272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  124. R. A. Clark, R. Watanabe, J. E. Teague et al., “Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients,” Science Translational Medicine, vol. 4, no. 117, Article ID 117ra7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. K. A. Thursky, L. J. Worth, J. F. Seymour, H. Miles Prince, and M. A. Slavin, “Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab,” British Journal of Haematology, vol. 132, no. 1, pp. 3–12, 2006. View at Publisher · View at Google Scholar · View at Scopus
  126. H. M. Gibson, A. Mishra, D. V. Chan, T. S. Hake, P. Porcu, and H. K. Wong, “Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome,” The Journal of Investigative Dermatology, vol. 133, no. 1, pp. 249–257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  127. H. K. Wong, A. J. Wilson, H. M. Gibson et al., “Increased expression of CTLA-4 in malignant T cells from patients with mycosis fungoides - Cutaneous T-cell lymphoma,” Journal of Investigative Dermatology, vol. 126, no. 1, pp. 212–219, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Patnaik, S. P. Kang, D. Rasco et al., “Phase i study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors,” Clinical Cancer Research, vol. 21, no. 19, pp. 4286–4293, 2015. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. Chvatchko, A. J. Hoogewerf, A. Meyer et al., “A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock,” The Journal of Experimental Medicine, vol. 191, no. 10, pp. 1755–1764, 2000. View at Publisher · View at Google Scholar · View at Scopus
  130. M. Duvic, L. C. Pinter-Brown, F. M. Foss et al., “Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma,” Blood, vol. 125, no. 12, pp. 1883–1889, 2015. View at Publisher · View at Google Scholar · View at Scopus
  131. X. Ni, T. Langridge, and M. Duvic, “Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab,” OncoImmunology, vol. 4, no. 7, Article ID e1011524, 2015. View at Publisher · View at Google Scholar · View at Scopus
  132. M. Sugaya, S. Morimura, H. Suga et al., “CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis,” The Journal of Dermatology, vol. 42, no. 6, pp. 613–615, 2015. View at Publisher · View at Google Scholar · View at Scopus
  133. D. Piancatelli, L. Bellotta, T. Del Beato, M. Duse, and M. R. Della Penna, “Total il-12 levels are increased in paediatric atopic dermatitis: correlations with age and disease severity,” International Journal of Immunopathology and Pharmacology, vol. 21, no. 2, pp. 359–365, 2008. View at Google Scholar · View at Scopus
  134. N. Kondo, E. Matsui, H. Kaneko et al., “Reduced interferon-γ production and mutations of the interleukin-12 receptor β2 chain gene in atopic subjects,” International Archives of Allergy and Immunology, vol. 124, no. 1–3, pp. 117–120, 2001. View at Publisher · View at Google Scholar · View at Scopus
  135. J. K. Eun, M. L. Won, S. H. Jung, H. R. Nam, S. J. Dong, and R. K. Jae, “mRNA expression and RNA editing (2451 C-to-U) of IL-12 receptor β2 in adult atopic patients,” Journal of Korean Medical Science, vol. 21, no. 6, pp. 1070–1074, 2006. View at Publisher · View at Google Scholar · View at Scopus
  136. A. H. Rook, G. S. Wood, E. K. Yoo et al., “Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses,” Blood, vol. 94, no. 3, pp. 902–908, 1999. View at Google Scholar · View at Scopus
  137. M. A. Wasik, “IL-13 as a novel growth factor in CTCL,” Blood, vol. 125, no. 18, pp. 2737–2738, 2015. View at Publisher · View at Google Scholar · View at Scopus
  138. L. J. Geskin, S. Viragova, D. B. Stolz, and P. Fuschiotti, “Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation,” Blood, vol. 125, no. 18, pp. 2798–2805, 2015. View at Publisher · View at Google Scholar
  139. N. A. Hanania, M. Noonan, J. Corren et al., “Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies,” Thorax, vol. 70, no. 8, pp. 748–756, 2015. View at Publisher · View at Google Scholar · View at Scopus
  140. L. A. Beck, D. Thaçi, J. D. Hamilton et al., “Dupilumab treatment in adults with moderate-to-severe atopic dermatitis,” New England Journal of Medicine, vol. 371, no. 2, pp. 130–139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  141. J. D. Hamilton, M. Suárez-Fariñas, N. Dhingra et al., “Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 134, no. 6, pp. 1293–1300, 2014. View at Publisher · View at Google Scholar · View at Scopus
  142. A. Tsianakas and T. A. Luger, “The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis,” Expert Opinion on Biological Therapy, vol. 15, no. 11, pp. 1661–1664, 2015. View at Publisher · View at Google Scholar · View at Scopus
  143. V. Sigurdsson, J. Toonstra, I. C. Bihari, C. A. F. M. Bruijnzeel-Koomen, W. A. van Vloten, and T. Thepen, “Interleukin 4 and interferon-γ expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immuno-histochemical study,” Journal of Cutaneous Pathology, vol. 27, no. 9, pp. 429–435, 2000. View at Publisher · View at Google Scholar · View at Scopus
  144. J. H. Woo, Y.-J. Lee, D. M. Neville, and A. E. Frankel, “Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials,” Methods in Molecular Biology, vol. 651, pp. 157–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  145. A. H. Rook, “The beauty of TLR agonists for CTCL,” Blood, vol. 119, no. 2, pp. 321–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  146. A. O. Huen and A. H. Rook, “Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma,” Current Opinion in Oncology, vol. 26, no. 2, pp. 237–244, 2014. View at Publisher · View at Google Scholar · View at Scopus
  147. M. C. Martínez-González, M. M. Verea-Hernando, M. T. Yebra-Pimentel, J. Del Pozo, M. Mazaira, and E. Fonseca, “Imiquimod in mycosis fungoides,” European Journal of Dermatology, vol. 18, no. 2, pp. 148–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. N. Onsun, H. Ufacik, Y. Kural, E. Topçu, and A. Somay, “Efficacy of imiquimod in solitary plaques of mycosis fungoides,” International Journal of Tissue Reactions, vol. 27, no. 4, pp. 167–172, 2005. View at Google Scholar · View at Scopus
  149. M. J. Deeths, J. T. Chapman, R. P. Dellavalle, C. Zeng, and J. L. Aeling, “Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream,” Journal of the American Academy of Dermatology, vol. 52, no. 2, pp. 275–280, 2005. View at Publisher · View at Google Scholar · View at Scopus
  150. Y. H. Kim, M. Girardi, M. Duvic et al., “Phase i trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma,” Journal of the American Academy of Dermatology, vol. 63, no. 6, pp. 975–983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. Y. H. Kim, D. Gratzinger, C. Harrison et al., “In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study,” Blood, vol. 119, no. 2, pp. 355–363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  152. I. Sagiv-Barfi, H. E. Kohrt, L. Burckhardt, D. K. Czerwinski, and R. Levy, “Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma,” Blood, vol. 125, no. 13, pp. 2079–2086, 2015. View at Publisher · View at Google Scholar · View at Scopus
  153. H. Fujita, “The role of IL-22 and Th22 cells in human skin diseases,” Journal of Dermatological Science, vol. 72, no. 1, pp. 3–8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  154. T. Miyagaki, M. Sugaya, H. Suga et al., “IL-22, but not IL-17, Dominant environment in cutaneous T-cell lymphoma,” Clinical Cancer Research, vol. 17, no. 24, pp. 7529–7538, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. M. B. Kuppala, S. B. Syed, S. Bandaru, S. Varre, J. Akka, and H. P. Mundulru, “Immunotherapeutic approach for better management of cancer—role of IL-18,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 11, pp. 5353–5361, 2012. View at Publisher · View at Google Scholar · View at Scopus
  156. Y. Amo, Y. Ohta, Y. Hamada, and K. Katsuoka, “Serum levels of interleukin-18 are increased in patients with cutaneous T-cell lymphoma and cutaneous natural killer-cell lymphoma,” The British Journal of Dermatology, vol. 145, no. 4, pp. 674–676, 2001. View at Publisher · View at Google Scholar · View at Scopus
  157. K.-I. Yamanaka, R. Clark, R. Dowgiert et al., “Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma,” Clinical Cancer Research, vol. 12, no. 2, pp. 376–382, 2006. View at Publisher · View at Google Scholar · View at Scopus
  158. H. Park, D. Byun, T. S. Kim et al., “Enhanced IL-18 expression in common skin tumors,” Immunology Letters, vol. 79, no. 3, pp. 215–219, 2001. View at Publisher · View at Google Scholar · View at Scopus
  159. M. J. Robertson, J. Kline, H. Struemper et al., “A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-hodgkin Lymphoma,” Journal of Immunotherapy, vol. 36, no. 6, pp. 331–341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  160. M. Aral, O. Arican, M. Gul et al., “The relationship between serum levels of total IgE, IL-18, IL-12, IFN-γ and disease severity in children with atopic dermatitis,” Mediators of Inflammation, vol. 2006, Article ID 73098, 4 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  161. K. Zedan, Z. Rasheed, Y. Farouk et al., “Immunoglobulin E, interleukin-18 and interleukin-12 in patients with atopic dermatitis: correlation with disease activity,” Journal of Clinical and Diagnostic Research, vol. 9, no. 4, pp. WC01–WC05, 2015. View at Publisher · View at Google Scholar · View at Scopus
  162. H. Konishi, H. Tsutsui, T. Murakami et al., “IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 17, pp. 11340–11345, 2002. View at Publisher · View at Google Scholar · View at Scopus
  163. T. Mehra, K. Ikenberg, R. M. Moos et al., “Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome,” JAMA Dermatology, vol. 151, no. 1, pp. 73–77, 2015. View at Publisher · View at Google Scholar · View at Scopus
  164. R. Chiarle, A. Podda, G. Prolla, J. Gong, G. J. Thorbecke, and G. Inghirami, “CD30 in normal and neoplastic cells,” Clinical Immunology, vol. 90, no. 2, pp. 157–164, 1999. View at Publisher · View at Google Scholar · View at Scopus
  165. D. L. Petersen, T. Krejsgaard, J. Berthelsen et al., “B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL),” Leukemia, vol. 28, no. 10, pp. 2109–2112, 2014. View at Publisher · View at Google Scholar · View at Scopus